According to a study published by Insure Insights, the global cell analysis system market is expected to grow at a CAGR of 8.9% during the forecast period. Cell analysis is the process of studying the characteristics of cells, including their shape, size, and presence of specific proteins. In addition, it also helps to examine cellular processes such as proliferation and growth. Cell analysis instruments play a vital role in drug development and production. These instruments are employed in various sectors such as pharmaceutical, biotechnology, hospitals, research institutes, and laboratories. The instrument performs several evaluation functions such as cell identification, cell structure studies, cell interaction, cell proliferation, single cell analysis, cell counting, quality control, and cell signaling.

Top Driver: Increasing Chronic Diseases Incidents and Rising Healthcare Expenditure

Attempts for reducing the time and cost involved in drug discovery, increase incidents of chronic diseases such as cancer and diagnostics laboratories, technological innovations, rise in outsourcing of drug discovery services, government initiatives are some of the major factors driving the growth for global cell analysis instruments market. Besides, rising healthcare expenditure and expanding cell-based research activities are expected to fuel the market growth.

On the other hand, the extravagant cost of cell analysis systems and lack of skilled personnel are factors hindering the growth of the global cell analysis system market.

Flow Cytometry Products to Make Crucial Contribution to Growth of Global Cell Analysis System Market

On the basis of product, the market is can be segmented into Flow Cytometry Products, qPCR Products, Cell Microarrays, Microscopes, Spectrophotometers, Cell Counters, HCS Systems, Other Products. The flow cytometry products segment accounted for the largest market share. The growing adoption of flow cytometry products in research and academia, increasing prevalence of chronic diseases and increasing technological advancements could be some major factors anticipating the segment growth. On the basis of process, the market is segmented into Cell Proliferation, Cell Counting and Quality Control, Cell Interaction, Target Identification, Cell Identification, Cell Viability, Cell Signaling Pathways/Signal Transduction, Validation, Single-cell Analysis. On the basis of end use the market is segmented in Research Institutes, Pharmaceutical & Biotechnology Companies and CROs, Hospitals and Diagnostic Laboratories, Cell Culture Collection Repositories, Others.

Rising Investments in Research to Benefit North America Market

North America is estimated to be the largest market for share, followed by Europe. Furthermore, the key factors such as the presence of a favorable business environment, the surge in government support through funds and grants would help the industry propel in the forecast period. The growth in number of research activities coupled with the surge in number of drug discovery initiatives by pharmaceutical & biotechnology companies in the US, and the strong presence of key players in this region are boosting the growth of the market in North America.

Players to Focus on Cell Analysis System Market

The global market is expected to stay fragmented with the increase in the number of new entrants in the coming years. Danaher Corporation, Becton, Dickinson and Company, Merck KGaA, GE Healthcare, Agilent Technologies, Olympus Corporation, Thermo Fisher Scientific, PerkinElmer, Promega Corporation, Tecan Group, Miltenyi Biotec, Carl Zeiss, Bio-Rad Laboratories, Sysmex Corporation, BioStatus Limited, NanoCellect Biomedical, Cell Biolabs, Creative Bioarray, Meiji Techno, and Cytek Biosciences among others could be at the forefront of the competition in the global market.

GE Electric: In December 2019, the European Commission had approved, under the EU Merger Regulation, the proposed acquisition of General Electric’s Healthcare Life Sciences Biopharma Business by Danaher Corporation. The approval is conditional on the divestiture of a remedy package.

BD Life Sciences: In August 2015, BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) announced it had completed the acquisition of Cellular Research, Inc.

Scope of the Report

By Product

• Flow Cytometry Products
• qPCR Products
• Cell Microarrays
• Microscopes
• Spectrophotometers
• Cell Counters
• HCS Systems
• Other Products

By Process

• Cell Proliferation
• Cell Counting and Quality Control
• Cell Interaction
• Target Identification
• Cell Identification
• Cell Viability
• Cell Signaling Pathways/Signal Transduction
• Validation
• Single-cell Analysis

By End-User

• Research Institutes
• Pharmaceutical & Biotechnology Companies and CROs
• Hospitals and Diagnostic Laboratories
• Cell Culture Collection Repositories
• Others

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.